NO972623L - Farmasöytisk blanding omfattende lamotrigin - Google Patents

Farmasöytisk blanding omfattende lamotrigin

Info

Publication number
NO972623L
NO972623L NO972623A NO972623A NO972623L NO 972623 L NO972623 L NO 972623L NO 972623 A NO972623 A NO 972623A NO 972623 A NO972623 A NO 972623A NO 972623 L NO972623 L NO 972623L
Authority
NO
Norway
Prior art keywords
pct
lamotrigine
pharmaceutical composition
date jun
sec
Prior art date
Application number
NO972623A
Other languages
English (en)
Other versions
NO972623D0 (no
Inventor
Simon Philip Hiskett
Susan Ann Taylor
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO972623D0 publication Critical patent/NO972623D0/no
Publication of NO972623L publication Critical patent/NO972623L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

En farmasøytisk blanding omfatter (a) fra 0.5 til 50 vekt % av lamotrigin eller farmasøytisk akseptabelt syreaddisjonssalt derav (b) fra 15til10vekt%laktose (c) fra 15 til 50 vekt % stivelse (d) fra 0.5 til 15 vekt % krystallinsk cellulose, og (e) fra 5.0 til 15 vekt % polyvinylpyrrolidon, og som er i form av et frittflytende pulver av granuler med følgende egenskaper: (I) ingen granuler har en partikkelstørrelse større enn 850^Jm (II) minst 90 vekt % av granulene har en partikkelstørrelse på fra 5 til SSOpm (III) granulene desintegrerer i løpet av 30 minutter i følge desintegreringstesten i den japanske Phannacopoeia, tolvte utgave, 1991, og (IV) minst 90 vekt % av lamotriginet eller lamotriginsaltet i granulene løser seg i løpet av 30 minutter når granulene underkastes oppløsningstesten, metode 2 (bladrøre metoden) i den japanske Pharmacopoeia, tolvte utgave, 1991.
NO972623A 1994-12-07 1997-06-06 Farmasöytisk blanding omfattende lamotrigin NO972623L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9424766.5A GB9424766D0 (en) 1994-12-07 1994-12-07 Pharmaceutical composition
PCT/GB1995/002865 WO1996017611A1 (en) 1994-12-07 1995-12-07 Pharmaceutical composition comprising lamotrigine

Publications (2)

Publication Number Publication Date
NO972623D0 NO972623D0 (no) 1997-06-06
NO972623L true NO972623L (no) 1997-08-06

Family

ID=10765604

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972623A NO972623L (no) 1994-12-07 1997-06-06 Farmasöytisk blanding omfattende lamotrigin

Country Status (19)

Country Link
US (1) US5861179A (no)
EP (1) EP0797441B1 (no)
JP (1) JP2977284B2 (no)
CN (1) CN1174505A (no)
AT (1) ATE213633T1 (no)
AU (1) AU696406B2 (no)
BR (1) BR9509975A (no)
CA (1) CA2207284A1 (no)
CZ (1) CZ171797A3 (no)
DE (1) DE69525649T2 (no)
ES (1) ES2172600T3 (no)
FI (1) FI972434A (no)
GB (1) GB9424766D0 (no)
HU (1) HUT77367A (no)
NO (1) NO972623L (no)
NZ (1) NZ296573A (no)
PL (1) PL320560A1 (no)
RU (1) RU2160106C2 (no)
WO (1) WO1996017611A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
JPH11506473A (ja) * 1997-02-25 1999-06-08 ザ、プロクター、エンド、ギャンブル、カンパニー 湿式粒状化方法
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法
CN1183240C (zh) * 1999-06-21 2005-01-05 宝洁公司 在不合格尺寸颗粒循环利用的流化床成粒机中制备粒状洗涤剂的方法
CA2439468A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
AU2003234240A1 (en) * 2002-04-23 2003-11-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004082587A2 (en) * 2003-03-21 2004-09-30 Ranbaxy Laboratories Limited Stable lamotrigine pharmaceutical compositions and processes for their preparation
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
PL1663182T5 (pl) 2003-09-12 2020-07-27 Amgen Inc. Szybko rozpuszczalna formulacja cynakalcetu HCI
CN1964723B (zh) * 2004-05-31 2011-06-22 千寿制药株式会社 大分子化合物的细颗粒在制造透明组织可视化制剂中的应用
WO2008104996A2 (en) * 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
CA2792046C (en) 2010-03-04 2014-12-02 Wockhardt Limited Modified release dosage form
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
AR227521A1 (es) * 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
AU635040B2 (en) * 1989-06-30 1993-03-11 Sumitomo Electric Industries, Ltd. Substrate having a superconductor layer
GB2278057B (en) * 1991-01-30 1995-02-01 Wellcome Found Water-dispersible tablets containing lamotrigine
FR2671970B1 (fr) * 1991-01-30 1995-06-23 Wellcome Found Comprimes dispersables dans l'eau.
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700114A1 (fr) * 1993-01-07 1994-07-08 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
FR2702149B1 (fr) * 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets

Also Published As

Publication number Publication date
CA2207284A1 (en) 1996-06-13
JPH10510255A (ja) 1998-10-06
CZ171797A3 (en) 1997-11-12
BR9509975A (pt) 1998-06-09
HUT77367A (hu) 1998-03-30
ATE213633T1 (de) 2002-03-15
JP2977284B2 (ja) 1999-11-15
NZ296573A (en) 1997-08-22
AU696406B2 (en) 1998-09-10
MX9704103A (es) 1997-09-30
CN1174505A (zh) 1998-02-25
NO972623D0 (no) 1997-06-06
GB9424766D0 (en) 1995-02-08
EP0797441A1 (en) 1997-10-01
US5861179A (en) 1999-01-19
WO1996017611A1 (en) 1996-06-13
DE69525649D1 (de) 2002-04-04
EP0797441B1 (en) 2002-02-27
FI972434A0 (fi) 1997-06-06
ES2172600T3 (es) 2002-10-01
RU2160106C2 (ru) 2000-12-10
DE69525649T2 (de) 2002-09-05
PL320560A1 (en) 1997-10-13
FI972434A (fi) 1997-06-09
AU4121196A (en) 1996-06-26

Similar Documents

Publication Publication Date Title
NO972623L (no) Farmasöytisk blanding omfattende lamotrigin
DK0858328T3 (da) Stabile præparater indeholdende N-propargyl-1-aminoindan
NO963053L (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO952321D0 (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
BR9609847A (pt) Derivados de N-(4-Benzila-substituída)-2-aminolactam
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
SE9401596D0 (sv) New compounds
FR2700116B1 (fr) Application d'anticonvulsivants comme radioprotecteurs.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application